American Statistical Association
In this talk, I will present a synthesis of Phase I trials that have used statistical models to guide dose escalation to determine the maximum tolerated dose (MTD) with the aim of understanding how these designs work in practice. The objective is to bring attention to how do these model-guided dose-finding algorithms, which are often viewed as black boxes to clinicians, work in real Phase I trials. In this synthesis, we address the broader clinical issues, like safety, overdose or underdose that arise when model based designs guide the dose escalation and determine the final MTD. I will provide a review of completed, model based Phase I trials and focus on specific examples where the design set-up lead to logistical challenges. Finally, I will discuss the definition and what exactly qualifies as a systematic review of the literature for educational purposes.
|Date:||Wednesday, November 6, 2013|
|Time:||4:00 - 5:00 P.M.|
Memorial Sloan-Kettering Cancer Center
Department of Epidemiology and Biostatistics
307 East 63rd Street
(between First and Second Avenues)
3rd Floor Conference Room
New York, New York
Note: To gain access to the building, please follow the directions by the telephone in the foyer.